ReNAgade Therapeutics Unveils Integrated RNA Delivery Platform and Secures $300M Series A Financing

On May 23, ReNAgade Therapeutics’ “all-in-one” RNA drug delivery system made its debut, successfully securing $300 million in Series A financing.

The company is dedicated to the research and development of RNA therapies, aiming to leverage the integration of its platform and technology to enable the delivery of RNA drugs to a broader range of human tissues and cells beyond the liver. This technology is claimed to expand the current scope of RNA therapeutics, holding promise for applications in the treatment of various diseases. The financing round was co-led by biotechnology investment firms MPM BioImpact and F2 Ventures.

Establishing a successful biotechnology startup is highly challenging, particularly as the mass exodus of investors from the sector since late last year and the sharp downturn in the biopharmaceutical market have made incubating startups an even more arduous task.

Since 2021, the Series A financing amounts for U.S. startups have declined for five consecutive quarters,In such a market environment, MPM BioImpact, as a subsidiary of the established biotechnology venture capital firm MPM Capital,ReNAgade still secured a substantial $300 million in Series A financing, far exceeding the fundraising amounts of most biotechnology companies this year.surpassing the $270 million financing round announced in April by another RNA company, Orbital Therapeutics.

Prior to ReNAgade, MPM BioImpact also incubated another star circular RNA drug startup, Orna Therapeutics, and led its $80 million Series A financing round.Series A investors have always been the “trendsetters” in the biotechnology startup ecosystem. MPM BioImpact’s extensive and deep positioning in the RNA field demonstrates its foresight regarding future technological trends.

Why Has ReNAgade Therapeutics Secured Massive Funding in This Sector?How has financing progressed in the RNA therapeutics sector in recent years?

ReNAgade is built on a bold idea—pushing the boundaries of RNA therapeutics. To this end, ReNAgade has chosen to establish a joint venture with Orna, aiming to achieve early validation of the technologies launched by ReNAgade.

All four founders of ReNAgade Therapeutics are veterans in the field of RNA therapeutics, with several having held key leadership positions at Moderna.

Amit D. Munshi, Chief Executive Officer, has decades of leadership experience in biotechnology companies and recently served as the CEO of Arena Pharmaceuticals, a well-established biotech firm.

Dr. Peter Smith, Chief Scientific Officer, previously served as Chief Early Development Officer at Alnylam, a leading company in the RNA therapeutics field, and has over three years of non-clinical R&D experience at Moderna.

Chief Operating Officer Dr. Ciaran Lawlor previously worked at Boston Consulting Group and has led multiple scientific initiatives, including those at Moderna.

Chief Business Officer Brian Shuster previously served at Johnson & Johnson, where he led the company’s acquisition and equity investment initiatives, and was responsible for strategic and financing transactions with biotechnology companies at J.P. Morgan.

ReNAgade has assembled a leadership team with deep expertise in RNA drug delivery and translational science, targeting therapeutic areas and targets currently unaddressed by existing RNA therapies. Leveraging its innovative platform and achievements, the company has garnered significant attention from investors in the current competitive landscape.

Since 2018, a total of 11 RNA therapies have received FDA approval, and multiple companies dedicated to the development of circular RNA drugs have successively secured substantial financing.It is evident that circular RNA therapeutics have become a hot research focus within the industry.。

ReNAgade, as a startup, has launched a comprehensive and complementary RNA drug production platform against the backdrop of current research, dedicated to breaking through the existing bottlenecks in RNA therapeutics.

Amit Munshi, CEO of ReNAgade Therapeutics, stated, “For many companies, delivery has been an overlooked issue and an afterthought. If you cannot target the correct cell or tissue type, or the right organ, a company’s capabilities will be severely limited over time.”

ReNAgade is developing novel lipid nanoparticles (LNPs) capable of entering various tissues and organs, integrating tools for RNA editing and gene insertion to build a multifunctional technology platform.

Munshi said, “At present, you will see many companies focusing on circular RNA, gene editing, or seeking new insertion technologies.”, but it is rare to find all of the aforementioned technologies within a single company..” ReNAgade andStar Companies in the R&D and Production of Circular RNA DrugsBoth Orna Therapeutics and pharmaceutical giant Merck have established collaborations, including a joint venture with Orna focused on delivery technologies.

Orna subsequently established a partnership with Merck & Co. and secured $100 million in equity investment,This means that Merck will be involved in the majority of the production work for this joint venture.。

As a major pharmaceutical manufacturer in the industry, Merck developed an interest in RNA-based therapeutics at an early stage. In 2006, Merck acquired Sirna Therapeutics, a company dedicated to the research and development of RNA interference drugs; however, eight years later, Merck wrote off this acquisition. Furthermore, Merck has maintained a long-standing relationship with Moderna, initially taking an equity stake in the company in 2015 and collaborating on the development of several experimental cancer vaccines. Although Merck has been engaged in RNA drug research for many years, it has not yet launched any approved products.Merck has now shifted its focus to the field of circular RNA therapeutics, aiming to deliver a range of novel drugs and vaccines.

Bolstered by substantial funding, Orna believes its first project—an experimental cancer therapeutic—will enter clinical testing in 2024. Merck also cited Orna’s preclinical data in its statement, noting that the data demonstrated the potential of circular RNA drugs for therapeutic applications across multiple areas, including vaccines and oncology.

In contrast,ReNAgade’s work is still in its early stages; the company has not disclosed which diseases it aims to treat, nor how far its drug candidates are from entering clinical trials.. Munshi also did not announce which organizations the company initially focused on, but he pointed out that ReNAgade’s goal is to use its drugs to target immune cells, kidney cells, or muscle cells.

Since its founding in 2021, ReNAgade Therapeutics has filed more than 100 patents and employed approximately 100 staff members, many of whom previously worked at major RNA therapeutics companies such as Alnylam Pharmaceuticals and Moderna.

Meanwhile, ReNAgade Therapeutics is also well-capitalized. Its $300 million Series A financing round far exceeds the funding raised by most biotechnology companies this year.This Series A financing round will provide the startup ReNAgade Therapeutics with several years of financial breathing room.. This capital foundation will not only enable ReNAgade Therapeutics to accelerate its growth and reach critical scale, but also help the company weather the current industry downturn.

By leveraging innovative delivery technologies alongside genomic and medical tools, ReNAgade has set ambitious goals from its inception. It aims to develop next-generation RNA therapeutics capable of targeting various tissue cell types, providing effective treatment options for a broader patient population and driving transformation in the field of RNA medicine.

Since its initial proposal in 1978, the research and development of RNA therapeutics has spanned several decades; however, the number of RNA drugs currently available on the market remains exceedingly limited.

Due to the inherent structural characteristics of RNA, these therapeutics are highly susceptible to interference from the immune system and cellular barriers, making it difficult for them to reach intracellular target sites. Therefore, RNA-based drugs require an appropriate delivery system that not only provides effective protection and encapsulation but also facilitates penetration into target cells and tissues, thereby enabling the drug to exert its therapeutic effects at intracellular targets.

In addition to companies like Alnylam that focus on RNA therapeutics, major pharmaceutical manufacturers such as Novartis, Merck, and Pfizer have also begun researching small-molecule drugs targeting various RNA molecules, aiming to unlock previously undruggable targets and expand the scope of RNA-based therapies.

In recent years, the most popular and heavily funded therapeutic approach has been circular RNA drugs.This class of small nucleic acid molecules, which occur naturally in cells, is considered to have broad development prospects. Traditional mRNA molecules are linear and unstable, and are rapidly degraded by enzymes in the body, making it challenging to develop therapies with durable effects. Circular RNA drugs aim to overcome a key limitation of mRNA molecules—their short shelf life. Circular RNAs lack terminal caps and do not possess sites susceptible to hydrolytic enzyme activity. In the circular RNA field, both Laronde and Orna have raised substantial amounts of capital.

Furthermore, transfer RNA is also one of the most popular therapeutic approaches.It transports and delivers the molecular building blocks required for cells to manufacture proteins. Alltrna, a startup founded in 2018, focuses on research into transfer RNA therapeutics, while Shape Therapeutics, Tevard Biosciences, and HC Biosciences are also engaged in the development of transfer RNA.

Self-amplifying RNA has also garnered significant attention from investors.Compared with conventional mRNA, its key distinction lies in the ability to self-replicate using its own RNA sequence as a template. In addition to expressing the target protein, it carries sequences encoding an RNA-dependent RNA polymerase, thereby generating more saRNA copies. Replicate Biosciences, a startup focused on self-amplifying RNA therapeutics, made its debut by securing $40 million in Series A funding at the ATP conference, joining Strand Therapeutics and Kernal Biologics in the field of self-amplifying RNA research.

 RNA Therapy Startup Series A Funding Overview / Chart by VCBeat New Medicine

Although companies developing next-generation RNA therapeutic technologies remain in the early stages of drug development, some have already made rapid research progress. This cohort of emerging startups is focused on building next-generation RNA platform technologies, aiming to address challenges associated with traditional RNA tools as therapeutics and fill the current innovation gap in this field.

Although it will take many more years of research and clinical trials before the next generation of RNA-based drugs reaches the market, these companies have already raised hundreds of millions of dollars from venture capitalists, large pharmaceutical companies, and other investment groups, securing substantial financial backing. If their efforts succeed, RNA therapeutics could offer new treatment options for cancer, rare diseases, and chronic conditions affecting the organs, nervous system, and immune system.

Reference Article:

Merck pays startup Orna $150M as ‘circular RNA’ attracts industry interest，BioPharma Dive

ReNAgade debuts with $300M and an ‘all-in-one’ system for delivering RNA drugs，BioPharma Dive